In the future, analyses of circulating tumour DNA may enable the tracking of the response of subclinical disease to anti-HER2 with or without anti-ER treatment, and thereby aid both clinical management of patients and provide improved data for understanding the interaction of ER and HER2 signalling in patients. This evidence concerns the gene ERBB2 and neoplasm.